Business Wire

GCCA

20.2.2024 13:31:29 CET | Business Wire | Press release

Share
Start-ups Challenged to Help Develop Carbon Capture Technology for Global Industry’s Push to Net Zero

A pioneering international programme, which brings together tech start-ups and leading manufacturers in the pursuit of net zero, has launched.

Innovandi Open Challenge 2024 is run by the Global Cement and Concrete Association (GCCA), the industry’s leading international body which is focused on helping the global cement industry reduce its emissions and ultimately achieve net zero concrete.

Applications are being encouraged from start-ups from around the world, interested in working on the development of carbon capture use and storage, for low carbon cement and concrete. Innovative technologies are sought, which include process integrated and end-of-pipe CO2 capture and use, and help prevent the carbon being emitted into the atmosphere.

This will be the 3rd Innovandi Open Challenge and builds on the success of previous years. The first challenge, in 2022, also focused on the development of carbon capture technology, and two start-ups have already gone to pilot stage. The 15 start-ups shortlisted in last year’s 2nd Innovandi Challenge, to work on the development of low carbon concrete, are currently in discussion with manufacturers about forming partnerships.

Claude Loréa, the GCCA’s Cement, Innovation and ESG Director, said: “Our industry is committed to achieving net zero and the development of carbon capture technology is a key part of that work. Our world leading Innovandi Open Challenge programme has already seen remarkable progress being made in just two years, with start-ups and our member companies working together. We’re looking forward to seeing what this year’s applicants can bring, to build on the extensive work that is already underway across the world.”

All GCCA members who account for 80% of global cement production capacity outside of China, and a number of leading Chinese manufacturers, have committed to reaching net zero, by 2050, through the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first global industry to set out such a detailed plan. The GCCA has also recently signed a ground-breaking agreement to work together on decarbonisation with the China Cement Association (CCA).

The development of new technologies is a key part of the industry’s roadmap to net zero, and carbon capture and storage technology is expected to account for around 36% of total emission reductions by 2050.

The industry’s first industrial-scale cement plant equipped with CO2 capture technology is scheduled to be mechanically completed at the Heidelberg Materials site in Brevik, Norway, by the end of 2024, with several more plants expected to open by 2030.

Thomas Guillot, Chief Executive of the GCCA, said: “We already know CCUS technology works, with pilots and projects underway across the world, but it’s crucial to see what other innovations are out there, beyond our industry, that could help accelerate our net zero mission.

“We encourage applications from start-ups around the globe to join us in the urgent fight to limit global warming. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology to further develop CCUS, then you should be applying.”

Jonathan Cool, CEO of Ultra High Materials, a start-up which participated in last year’s Open Challenge, encouraged others to apply: “The support, guidance, exposure to the GCCA membership and the facilitation of collaborative opportunities with GCCA members has been effective, efficient and it's made a beneficial impact for all of us. Given the option to do it all again, we certainly would.”

Start-ups interested in applying to the third Innovandi Open Challenge, can click here for more information. The deadline for applications is 15th April.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220364304/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye